Merck Oncology Deal History & Licensing Activity
Merck Oncology is a large pharma headquartered in US. Over the past three years, Merck Oncology has been involved in 2 licensing and acquisition transactions, with a primary focus on Small Molecules (4 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
2
Active Trials
50
Top Modality
Small Molecules
Focus Area
Solid Tumors
Merck Oncology Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Merck Oncology in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| HRS-5346 | Merck | Small Molecules | Phase 2 | license | Jul 18, 2026 |
| TERN-701 | Merck | Small Molecules | Phase 1 | acquisition | Mar 25, 2026 |
Merck Oncology Pipeline Focus
Therapeutic areas and modalities where Merck Oncology is most active based on deal history and clinical trial data.
Therapeutic Areas
Merck Oncology Strategic Signals
Key indicators of Merck Oncology's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Merck Oncology Clinical Pipeline
Merck Oncology has 50 active clinical trials across 5 development phases.
3
Phase 4
2
Not Applicable
19
Phase 1
20
Phase 2
6
Phase 3
See How Your Asset Matches Merck Oncology's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Merck Oncology Licensing & Deal Activity
Merck Oncology is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Merck Oncology ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Merck Oncology include Solid Tumors (14 deals and trials), Hematological Malignancies (8 deals and trials), Option Deals (2 deals and trials), and Hematology (2 deals and trials). In terms of modality, Merck Oncology has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Merck Oncology and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Merck Oncology's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.